Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $166,649.60 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Get Free Report) EVP Joseph Baroldi sold 4,006 shares of the company's stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total value of $166,649.60. Following the completion of the transaction, the executive vice president now owns 19,631 shares in the company, valued at approximately $816,649.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Ionis Pharmaceuticals Price Performance

Shares of NASDAQ:IONS traded down $0.63 on Wednesday, hitting $40.91. The company's stock had a trading volume of 1,176,174 shares, compared to its average volume of 1,160,535. Ionis Pharmaceuticals, Inc. has a 1 year low of $34.32 and a 1 year high of $54.44. The company has a debt-to-equity ratio of 3.18, a current ratio of 5.90 and a quick ratio of 5.83. The company has a market capitalization of $5.96 billion, a PE ratio of -15.98 and a beta of 0.39. The company has a 50-day simple moving average of $44.43 and a 200 day simple moving average of $47.39.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last announced its earnings results on Wednesday, February 21st. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $0.72. The business had revenue of $325.00 million during the quarter, compared to analyst estimates of $176.01 million. Ionis Pharmaceuticals had a negative net margin of 46.32% and a negative return on equity of 90.29%. Ionis Pharmaceuticals's revenue for the quarter was up 113.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.37) earnings per share. Sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -4 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in IONS. PNC Financial Services Group Inc. boosted its stake in Ionis Pharmaceuticals by 2.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,378 shares of the company's stock worth $424,000 after buying an additional 202 shares in the last quarter. Grandfield & Dodd LLC boosted its stake in shares of Ionis Pharmaceuticals by 0.7% in the 4th quarter. Grandfield & Dodd LLC now owns 33,104 shares of the company's stock valued at $1,675,000 after purchasing an additional 242 shares in the last quarter. Captrust Financial Advisors grew its holdings in shares of Ionis Pharmaceuticals by 21.1% during the 2nd quarter. Captrust Financial Advisors now owns 1,429 shares of the company's stock valued at $53,000 after purchasing an additional 249 shares during the last quarter. Treasurer of the State of North Carolina raised its position in Ionis Pharmaceuticals by 0.5% in the 3rd quarter. Treasurer of the State of North Carolina now owns 62,532 shares of the company's stock worth $2,836,000 after purchasing an additional 310 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in Ionis Pharmaceuticals by 2.3% in the third quarter. Victory Capital Management Inc. now owns 15,436 shares of the company's stock worth $700,000 after purchasing an additional 348 shares during the last quarter. Institutional investors own 93.86% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. William Blair reiterated an "outperform" rating on shares of Ionis Pharmaceuticals in a research note on Tuesday, April 9th. Bank of America upgraded shares of Ionis Pharmaceuticals from a "neutral" rating to a "buy" rating and increased their target price for the stock from $52.00 to $62.00 in a research report on Tuesday, January 2nd. Piper Sandler boosted their price target on shares of Ionis Pharmaceuticals from $62.00 to $63.00 and gave the company an "overweight" rating in a research report on Thursday, February 22nd. Needham & Company LLC reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Ionis Pharmaceuticals in a report on Tuesday, April 9th. Finally, Oppenheimer lifted their price objective on shares of Ionis Pharmaceuticals from $72.00 to $75.00 and gave the company an "outperform" rating in a research note on Tuesday, April 9th. One research analyst has rated the stock with a sell rating, four have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $56.08.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.